A New Path for Weight Management Launched: UAE Sets Milestone with QSYMIA® Approval
UAE’s healthcare initiatives aim to combat rising obesity rates with innovative treatments
CAMPBELL, Calif., March 10, 2025 – VIVUS LLC has announced the market approval of QSYMIA® (phentermine and topiramate extended-release capsules) for the treatment of overweight and obesity among adults and children aged 12 and older. The United Arab Emirates (UAE) marks the first country within the Middle East to make QSYMIA available, marking not just approval but also hope for patients grappling with obesity.
VIVUS, working closely with PharmaAccess, its marketing partner for the Middle East and North African (MENA) region, aims to provide healthcare providers with expanded treatment options reflecting the UAE’s dedication to addressing the obesity crisis. Alphamed Drug Store, known as the exclusive distributor, will facilitate the distribution of QSYMIA.
“VIVUS remains steadfast in its mission to tackle the obesity crisis head-on,” said John Amos, Chief Executive Officer at VIVUS LLC. “With the availability of QSYMIA in the UAE, we’re not only broadening treatment access but also reaffirming our commitment to advancing patient care on a global scale.”
The urgency of combatting obesity cannot be overstated. According to the World Obesity Federation, the number of overweight and obese individuals may reach approximately 7.5 million by 2035 within the UAE alone. The societal impacts of these statistics are stark – obesity-related health complications are exerting serious strains on both individuals’ health and the UAE's economy.
“By providing access to QSYMIA, the UAE can truly make a difference for those affected by obesity, addressing the challenges of this epidemic,” remarked Santosh T. Varghese, MD, President of VIVUS Global Pharmaceutical Development. “This milestone not only reflects our commitment but also signifies progress toward alleviating the public health burden.”
On another front, UAE-based Klaim, specializing in healthcare payments solutions, is also making strides with the announcement of $10 million secured through Series A equity funding, complemented by another $16 million financing fund aimed at their expansion. This funding aligns with Klaim’s mission to revolutionize the healthcare financial ecosystem by facilitating quicker medical insurance claim payments, which will significantly help healthcare providers maintain cash flow.
The new infusion of capital will not only bolster Klaim’s presence within the UAE but also allows them to deploy resources to Saudi Arabia, Oman, and beyond. “Securing Series A funding is not only a major validation of our vision and business model but also the key inflection point for rapid scaling,” stated Karim Dakki, Co-Founder and CEO of Klaim. Their first transaction related to this new funding initiative is expected to occur this March, providing traction for their regional plans.
Recognizing the importance of healthcare providers is central to Klaim’s strategy; fostering financial stability among these entities is expected to lead to improved patient care and operational efficiency.
Klaim launched its ambitions within the Saudi market previously, thanks to its collaboration with Tharawat Tuwaiq Financial Company, which offers wealth management and financial advisory services. This strategic relationship seeks to pave the way for Klaim’s success amid the growing complexity and needs of the Saudi healthcare system.
VIVUS and Klaim’s advancements signify proactive actions being taken to address two pressing issues faced by the UAE — rising obesity rates and the need for efficient healthcare payment systems. Each company's response showcases the innovative approaches being adopted to combat public health challenges.
Both VIVUS and Klaim are not just committed to local initiatives; they are positioning themselves to contribute on a larger scale. QSYMIA and the newly established financial solutions present pathways to transform healthcare delivery, demonstrating the UAE's dedication to safeguarding public health and ensuring sustainable growth.
With obesity predicted to escalate, affecting one billion individuals globally by 2030, it's evident the time for solutions is now. Organizations like VIVUS and Klaim are leading the way, inspiring hope for millions impacted by obesity and the financial strains on healthcare providers.
For updates on QSYMIA, visit QSYMIA.com. For more information about Klaim and their services, follow updates on their official platforms as they continue to reshape the healthcare financial terrain.